Learn about the AAPS Foundation

Contact UsExecutive CouncilPolicies & GovernanceAwards, Fellows, and TravelshipsThe AAPS FoundationAffiliates and LinksCareers at

Meetinas

Annual Meeting & ExpositionNational Biotech ConferenceWorkshopsPast Meeting PresentationsContributed PapersSuggest

ProgrammingePostersPublished Meeting AbstractsFuture Annual EventsContinuing EducationPress Credentials eLearning

eCoursesWebinarsePosters

Career Center

Job SeekersEmployers & RecruitersAAPS Career FairNBC Career ResourcesProfessional DevelopmentContinuing EducationAAPS Salary Survey and Calculator

Publications

AAPS NewsmagazineAAPS JournalsAAPS BlogBooksPublished Meeting AbstractsMedia Kit and Editorial Calendar

News Press RoomIndustry NewsPharmaceutical Science UpdateU.S. Regulatory NewsSocial MediaPress Kit

Business with AAPS

Business OverviewAdvertisers, Exhibitors & SponsorsMember DemographicsList RentalMedia Kit and Editorial CalendarBuyers' Guide

You are Here: Home > Publications

Publications

AAPS NewsmagazineAAPS Journals

The AAPS JournalAAPS PharmSciTechPharmaceutical Research AAPS BlogBooksPublished Meeting AbstractsMedia Kit and Editorial Calendar

Current Trends in Monoclonal Antibody Development and Manufacturing

Current Trends in Monoclonal Antibody Development and Manufacturing

Publication Date: 2009-11-12

Edited by Steven J. Shire, Wayne Gombotz, Karoline Bechtold-Peters, and James Andya

Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups

involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade. Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. *Current Trends in Monoclonal Antibody Development and Manufacturing* will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.


ISBN: 978-0-387-76642-3

Suggested List Price: \$141.75 (AAPS member) \$189.00 (nonmember)

Order a copy today!

*Note: Prices are subject to change; for the most up-to-date prices, go to www.PharmaGateway.net or click on the above link to order the book.

My AAPS





Find us on: